Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Inclusion Criteria: * Patients aged \> 18 * Histologically proven diagnosis of cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors * Measurable disease (Response Evaluation Criteria in Solid Tumor \[RECIST\] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup \[GCIG\] criteria) or with histologically proven diagnosis of relapse * Disease in progression \> 6 months after a first or second platinum-based line. Patients should have previously received a taxane derivative. * ECOG performance status \< 2 * Life expectancy of at least 12 weeks * Adequate bone marrow, renal, and hepatic function Exclusion Criteria: * Ovarian tumors of low malignant potential * Non-epithelial ovarian or mixed epithelial/non-epithelial tumors * Previous radiotherapy * Prior diagnosis of malignancy * Bowel obstruction, sub-occlusive disease, or presence of symptomatic brain metastases * Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade \> 1 * History of congestive heart failure (New York Heart Association \[NYHA\] classification \> 2), history of myocardial infarction within the last 6 months, or history of atrial or ventricular arrhythmias * Severe active infection * Severe hypersensitivity to products containing Cremophor EL and/or to compounds chemically related to paclitaxel, carboplatin or Caelyx * Fertile women not using adequate contraceptive methods * Pregnant or breast feeding women